| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 8, 2022 | Another Indian drug manufacturer hit with a Form 483 over recent observations | Several Indian drug manufacturers have been put under a microscope by the FDA, as major generics manufacturers have been hit in recent months by Form 483s. And now Dr. Reddy’s Laboratories is the latest to get the sl... |
| Apr 21, 2022 | Reify Health’s Mission to Transform Healthcare | The Journey from a $30M to $2.2B Valuation in 30 Months
The founders of Reify Health, Ralph Passarella and Michael Lin, have always firmly believed that the bottleneck to curing deadly diseases like cancer and Alzheimer’s is clinical trial ... |
| Mar 24, 2022 | Merck to stop making APIs at Pennsylvania site and cut 300 jobs by 2024 | In 2024, Merck will discontinue its manufacturing of active pharmaceutical ingredients. And with that move, it will no longer need its Cherokee manufacturing site in Danville, PA.
The site will close when API production stops, the company s... |
| Nov 18, 2021 | Stem cell specialist Ncardia bags new funds to help scale manufacturing ops | A Belgian cell therapy company has secured $60 million in funding to strengthen its manufacturing operations, and grow the cell and gene therapy ecosystem across the world.
Ncardia landed the funding from Kiniciti, a... |
| Sep 27, 2021 | Can Virtual Testing Reduce Bias in Clinical Trials? Lightship Raises $40M to Try | As the pandemic slowed and halted clinical trials to test new drugs, the need for a virtual solution became clear to clinical researchers. El Segundo-based Lightship hopes to keep clinical trials going with a virtual process that allows pat... |
| Sep 27, 2021 | A New Breed of Clinical Study Is Emerging After FDA Allows Virtual Trials | As the pandemic slowed and halted clinical trials to test new drugs, the need for a virtual solution became clear to clinical researchers. El Segundo-based Lightship hopes to keep clinical trials going with a virtual process that allows pat... |
| Dec 22, 2020 | A Dose Of Change In The Pharma Supply Chain | Kevin MacDonald, CEO of Kit Check, the leader in med kit restocking automation and drug diversion detection software for hospitals. |
| Jun 8, 2020 | Fate Of Pharma’s Reputation Lies In Gilead’s Hands On Pricing Of Covid-19 Drug Remdesivir | Few remember the time when the pharmaceutical industry was the world’s most admired. The leader was Merck, which was deemed by Fortune magazine to be the “World’s Most Admired Company” for seven straight years starting in 1987. As recently ... |
| Mar 10, 2020 | Data: The Difference Between Life, Death And Profit? | On February 4th, 2020, Gilead’s Remdesivir entered clinical trials to treat the coronavirus. The drug was originally developed to combat the Ebola outbreak but is now being deployed for stage 3 trials in cooperation with Chinese authorities... |
| Nov 14, 2018 | Precision medicine will have a transformative effect on clinical trials | Clinicians, researchers, and societies have no shortage of information. That’s good news and bad news. Referential information is growing exponentially, thanks in part to the proliferation of publications. However, researchers and clinician... |
| Feb 22, 2018 | ‘It’s breathtaking’: A Chinese biotech CEO weighs in on policy changes remaking China’s FDA | With China’s biotech sector on the rise, changes are afoot at the agency tasked with regulating the country’s pipeline of new drugs.
In recent months, China’s version of the U.S. Food and Drug Administration, known as CFDA, has introduced a... |
| Feb 9, 2018 | What’s the future of clinical trial design? Medidata sees a blend of virtual and in-person components | Medidata’s fourth-quarter earnings call offered a glimpse of how the company, which develops cloud-based technology and analytics tools to plan and execute clinical studies, envisions the future of clinical trial design. Glen De Vries, cofo... |
| Dec 1, 2017 | Teva boots its R&D chief; Ironwood grows the C-suite and Intercept taps new EVP of research | Michael Hayden
→ In the first major C-suite overhaul under new CEO Kåre Schultz, troubled Teva is parting ways with R&D chief Michael Hayden, Global Specialty Medicines head Rob Koremans, and Global Generic Medicines ... |
| Jul 31, 2017 | A lab-testing company just inked a billion-dollar deal for a healthcare company you've never heard of | Aly Song / Reuters
A researcher prepares medicine at a laboratory in Nanjing University in Nanjing, Jiangsu province, April 29, 2011.
Lab-testing giant LabCorp just picked up contract research organization Chiltern for $1.2 billion.
Adverti... |
| Jul 20, 2017 | Wall Street is making huge bets on healthcare companies you've never heard of | REUTERS/Fred Prouser
Carlyle Group co-founder and Managing Director David Rubenstein
Advertisement
Wall Street is interested in the companies that help drugmakers research and develop drugs.
These companies, called contract research organiz... |
| Sep 29, 2016 | Pharmalot, Pharmalittle: Novo Nordisk cutting 1,000 jobs amid diabetes drug price war | Good morning, everyone, and nice to see you again. We are scrambling a bit after a late-night return from the STAT headquarters, but happy to be ensconced once again in the cozy confines of the Pharmalot campus, where we are quaffing cups o... |
| Sep 14, 2016 | Pharmalot, Pharmalittle: Sarepta stock jumps after critic of DMD drug leaves the FDA | Hello, everyone, and welcome to the middle of the week. Congratulations on making it this far. It is an accomplishment, after all. The next step is to forge ahead. And why not? Just consider the alternatives. On that optimistic note, please... |
| Aug 26, 2016 | Pharmalot, Pharmalittle: Mylan CEO claims ‘no one’s more frustrated than me’ | And so, another working week is about to draw to a close. Not a moment too soon, yes? After a busy few days, this is an opportunity to start daydreaming about weekend plans. Our agenda is rather modest. We plan to shepherd one of the short ... |
| Jul 29, 2016 | Pharmalot, Pharmalittle: Eli Lilly probed over contracts with pharmacy benefit managers | And so, another working week will soon draw to a close. It has taken a while to reach this point, though, yes? Well, this is an opportunity, nonetheless, to daydream about weekend plans. Our modest agenda includes catching up on reading and... |
| Jun 22, 2016 | Pharmalot, Pharmalittle: India revising laws to upgrade drug safety | Hello, folks, and how are you today? ’Tis the middle of the week, which calls for a celebratory cup of stimulation. After all, you made it this far, so why not forge ahead? Besides, a warm, shiny sun is enveloping the Pharmalot campus, whic... |
| Jun 20, 2016 | Pharmalot, Pharmalittle: Clinton gets the most pharma donations of any candidate | Hello, everyone, and welcome to another working week. It’s nice to see you again after our extended respite, which was exciting and fast-paced. Now, though, the usual routine has returned. But we all knew this would happen, yes? So as a shi... |
| Jun 2, 2016 | Pharmalot, Pharmalittle: Drug maker compliance reviews may have conflicts | Good morning, everyone, and apologies for the late start today. We encountered various technology and traffic challenges, unfortunately, but we are scrambling to get caught up. With that in mind, we are quaffing more cups of stimulation. As... |
| Apr 5, 2016 | Pharmalot, Pharmalittle: Rising drug prices cost workers’ compensation programs | Good morning, everyone, and how are you today? A bright, shiny sun is enveloping the Pharmalot campus, although it is not yet enough to counteract the bitter cold. In fact, our short person, who is under the weather, is staying home to avoi... |
| Mar 4, 2016 | Pharmalot, Pharmalittle: Sanofi accelerates work on Zika vaccine, Moody’s lowers outlook for pharma | And so, another working week will soon draw to a close. This is, as you know, our treasured signal to daydream about weekend plans. Besides catching up on reading and naps, we look forward to spending time with our short people, one of whom... |
| Feb 17, 2016 | Pharmalot, Pharmalittle: Couple pledges millions to lower drug prices, more TV ads for speciality meds | Hello, everyone, and how are you today? We are just fine, thank you, especially since we have made it to the middle of the week. Even during a shortened workweek, this is a milestone worth celebrating. So please join us as we quaff a few cu... |
| Jan 20, 2016 | Pharmalot, Pharmalittle: Sale of cancer treatment halted, Ebola vaccine deal signed | Top of the morning to you. And a fine one, it is, although a bit nippy here on the Pharmalot campus, where a warm sun is shining, the shortest of short people has left for the local schoolhouse, and the official mascots are happily snoozing... |
| Dec 22, 2015 | Pharmalot, Pharmalittle: pricing Glaxo’s asthma medicine, twist in Valeant-Walgreens deal | Hello, everyone, and how are you today? We are doing just fine, thank you. Although gray skies are hovering over the Pharmalot campus this morning, our spirits remain as sunny as ever. In part, we attribute this to a few cups of stimulation... |
| May 6, 2015 | Mixette wants to bring back the mixtape | Instead of bemoaning the death of the mixtape, Kelly Snow built a high-tech answer to it.
It’s called Mixette and Snow, 27, of Chestnut Hill, is billing it as a way to give music as a gift. Users choose a song (one for $1.99, two for $2.99)... |
| Jan 14, 2015 | #JPM15 Day 2 Buzz: Drug pricing, catch-phrasing and positive vibes about healthcare | Photo from Flickr user Wally Gobetz
Promoted
Clinical Care Capacity Planning
Learn how to manage clinical care capacity more efficiently during uncertain times.
SAP
Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
T... |
| May 20, 2013 | GE offers an inside look at how it’s innovating in cancer care (video) | On the treatment side, researcher Reginald Smith says a team is developing new tools for the implementation of emerging targeted, cellular therapies in cancer. Last year, GE opened a new cell science lab in Wales and told Outsourcing-pharma... |
| Mar 13, 2013 | Report: Baxter to cut 400 in Puerto Rico | MassDevice.com On Call | MASSDEVICE ON CALL — Baxter (NYSE:BAX) told reporters this week that the company is cutting 400 positions from a facility in Puerto Rico, where it is also investing $35 million for a brand new manufacturing line.
The cuts represent 44% of t... |
| Jun 19, 2012 | Match.coms of clinical trials make it easier to connect patients, researchers | The formula for these recruiting sites is pretty standard: Aggregate sometimes-incomplete data from ClinicalTrials.gov, fill in missing data, develop a search algorithm and filter, and organize the data for certain audiences.
Earlier this y... |
| May 25, 2012 | Software fast enough for custom-made cancer treatments? | GenomOncology is on the cusp of launching. It’s started raising money for salaries, software costs and tumor sequencing. It wants to work with biopharmaceutical companies, cancer research groups and academic centers. For biopharmas, the ide... |
| Apr 17, 2012 | CDSCO expanding to enforce new clinical trial rules in India | By Stewart Eisenhart, Emergo Group
Indian regulators are adding staff and resources to the Central Drugs Standard Control Organization (CDSCO) in order to enforce more stringent clinical trial guidelines for medical devices and pharmaceutic... |
| Apr 16, 2012 | Bankruptcy court extends Cetero bidding deadline to May 11 | Cary, North Carolina-based Cetero filed for chapter 11 bankruptcy protection on March 26. The early phase CRO said in the court filings that its bankruptcy filing was prompted by financial constraints on the company after a U.S. Food and Dr... |
| Apr 13, 2012 | Cetero creditors cry foul on stalking horse bid process for bankrupt CRO | The Cetero bankruptcy filing said the company and its assets would be sold in a “stalking horse” auction. That process calls for a bidder, the stalking horse, to set a minimum bid for others to top. Typically, the stalking horse has the rig... |
| Mar 19, 2012 | Report: J&J set for EU OK on Synthes buyout | Wall Street Beat | European Union regulators are poised to give the OK to Johnson & Johnson‘s (NYSE:JNJ) $21.3 billion acquisition of Swiss orthopedic giant Synthes, according to Reuters.
The anti-trust regulators wrung concessions aimed at reducing J&... |
| Feb 29, 2012 | Icon’s PriceSpective acquisition adds drug price expertise to CRO’s portfolio | The PriceSpective deal follows completion of the BeijingWits Medical Consulting acquisition, which adds to Icon’s presence in China. Much of the CRO acquisition activity of the last year has been driven by the desire of large CROs to add sp... |
| Jan 11, 2012 | CRO industry rebound hinges on big pharma partnerships, Morningstar says | “We expect growth in the CRO industry to continue accelerating into 2012 and the rise of the strategic partnership model should concentrate these benefits in the hands of a select group of narrow-moat providers,” wrote Lauren Migliore, a Mo... |
| Aug 12, 2011 | CRO M&A: How pharma drives it and why private equity is interested in it | Consolidation among clinical research organizations has been ongoing for many years. The pace has picked up in 2011 and pharmas are driving it. Big pharma has been looking for ways to slash costs, feeding the outsourcing movement that has l... |
| Jul 29, 2011 | INC Research: No acquisitions in near future but CEO says ‘never say never’ | INC Research’s Kendle acquisition vaulted the North Carolina clinical research organization into the CRO industry’s top five and, according to CEO James Ogle, helped the company become a global player.
Ogle spoke with Outsourcing Pharma, a ... |
| Nov 15, 2010 | Ricerca Biosciences branches out | Faced with a recent slowdown in much of the contract research organization industry, Ricerca Biosciences LLC has tweaked its focus to solidify its future.
The Concord Township, Ohio-based company has shaken up its client base to include mor... |
| Nov 15, 2010 | Ricerca retrenches; CRO diversifies client, geographic base | Promoted
Telemedicine’s potential to provide healthcare to the world’s most vulnerable
Teladoc Health Head of R&D Yulun Wang highlights the impact of virtual care in underserved populations around the globe through the World Telehealth ... |
| Jul 28, 2010 | Second proxy advisory firm backs Charles River Labs/WuXi merger | Another proxy advisory firm is backing the proposed, $1.6 billion merger between WuXi PharmaTech (Cayman) Inc. (NYSE:WX) and Charles River Laboratories International Inc. (NYSE:CRL), which has drawn opposition from some of CRL’s top investo... |
| Jul 16, 2010 | Charles River, Wuxi PharmTech still on a roller coaster | It’s been a busy week for everyone concerned with a proposed, $1.6 billion merger between Charles River Laboratories International Inc. (NYSE: CRL) and WuXi PharmaTech (Cayman) Inc. (NYSE:WX).
Aiming to counter stiff opposition from some of... |
| Jul 16, 2010 | Top CRL investor unpersuaded on WuXi merger | It’s been a busy week for everyone concerned with a proposed, $1.6 billion merger between Charles River Laboratories International Inc. (NYSE: CRL) and WuXi PharmaTech (Cayman) Inc. (NYSE:WX).
Aiming to counter stiff opposition from some of... |
| Jul 15, 2010 | Proxy advisor backs CRL/WuXi merger | A proxy voting advisory service is recommending that shareholders approve the proposed, $1.6 billion merger of Charles River Laboratories International Inc. (NYSE:CRL) and WuXi PharmaTech (Cayman) Inc. (NYSE:WX).
PROXY Governance Inc.’s rep... |
| Jul 14, 2010 | FTC asks for more info on Charles River Labs buyout of WuXi Pharmatech | The proposed merger between WuXi PharmaTech (Cayman) Inc. (NYSE:WX) and Charles River Laboratories International Inc. (NYSE:CRL) hit another snag after the Federal Trade Commission asked both companies for more information on the deal.
The ... |
| Jul 13, 2010 | Charles River Labs seeks support for merger with WuXi | Facing opposition over its $1.6 billion merger with WuXi Pharmatech, Charles River Laboratories International is wooing support for the deal with a new investor presentation and positive responses from clients.
Looking to bolster support fo... |
| Jul 13, 2010 | Charles River Labs woos supporters for WuXi merger | Looking to bolster support for its proposed, $1.6 billion merger with Shanghai-based WuXi PharmaTech (Cayman) Inc. (NYSE:WX), Charles River Laboratories International Inc. (NYSE:CRL) is mounting a public relations push to tout the deal’s me... |
| Jun 18, 2010 | UPDATE: More top investors oppose Charles River Labs merger with WuXi | Two more top investors in Charles River Laboratories International Inc. (NYSE:CRL) voiced opposition to a proposed merger with WuXi PharmaTech (Cayman) Inc. (NYSE:WX), saying the deal is too risky.
Neuberger Berman LLC, in a June 16 letter ... |
| Jun 18, 2010 | More balk at WuXi PharmaTech-Charles River deal | Two more top investors in Charles River Laboratories International Inc. (NYSE:CRL) voiced opposition to a proposed merger with WuXi PharmaTech (Cayman) Inc. (NYSE:WX), saying the deal is too risky.
Neuberger Berman LLC, in a June 16 letter ... |
| #JPM15 Day 2 Buzz: Drug pricing, catch-phrasing and positive vibes about healthcare | Battles Over Drug Pricing
Lots of talk about the prices of drugs. Express Scrips got a lot of attention for saying it will continue to push back on the price of drugs particularly around cancer and high cholesterol. Two companies ready to f... |
| Charles River Labs seeks support for merger with WuXi | Facing opposition over its $1.6 billion merger with WuXi Pharmatech, Charles River Laboratories International is wooing support for the deal with a new investor presentation and positive responses from clients.
Looking to bolster support fo... |
| Match.coms of clinical trials make it easier to connect patients, researchers | Eighty percent of clinical trials are delayed at least one month because of unfulfilled enrollment, according to Cutting Edge Information. That means additional time and additional costs for trial sponsors.
Some have gotten creative in find... |
| Icon’s PriceSpective acquisition adds drug price expertise to CRO’s portfolio | Count Icon (NASDAQ:ICLR) among the clinical research organizations continuing the industry M&A activity.
The Ireland-based CRO has acquired PriceSpective, a CRO with a consulting focus and expertise in drug pricing. Icon didn’t disclose... |
| What’s the future of clinical trial design? Medidata sees a blend of virtual and in-person components | Medidata’s fourth-quarter earnings call offered a glimpse of how the company, which develops cloud-based technology and analytics tools to plan and execute clinical studies, envisions the future of clinical trial design. Glen De Vries, cofo... |
| Ricerca retrenches; CRO diversifies client, geographic base | Faced with a recent slowdown in much of the contract research organization (CRO) industry, Ricerca Biosciences LLC has tweaked its focus to solidify its future.
The Concord Township, Ohio-based company has shaken up its client base to inclu... |
| GE offers an inside look at how it’s innovating in cancer care (video) | Remember back in the fall of 2011 when GE committed $1 billion to cancer research and development? A new video put out by the GE Global Research Center commemorating National Cancer Research Month gives a glimpse into some of the work the m... |
| Cetero creditors cry foul on stalking horse bid process for bankrupt CRO | Cetero Research‘s unsecured creditors are challenging the bidding process for the clinical research organization claiming that the bankruptcy sale process is rigged in favor of the banks who are already lending to the company.
Outsourcing P... |
| CRO industry rebound hinges on big pharma partnerships, Morningstar says | Clinical research organizations are on a rebound and the CRO industry is poised for 2012 growth led by the largest CROs exercising deals with large pharmaceutical companies, according to a new report by investment research firm Morningstar.... |
| CRO M&A: How pharma drives it and why private equity is interested in it | INC Research’s June acquisition of Trident Clinical Research didn’t generate the same headlines among clinical research organizations as the company’s $232 million Kendle purchase. But it’s just as illustrative of what’s driving M&A tre... |
| Software fast enough for custom-made cancer treatments? | A new approach to review the genetic makeup of cancer patients and their tumors could enable customized cancer treatments.
It’s been too hard for scientists to analyze peoples’ genetic data. Figuring out the details behind a genome can take... |
| More balk at WuXi PharmaTech-Charles River deal | Two more top investors in Charles River Laboratories International Inc. (NYSE:CRL) voiced opposition to a proposed merger with WuXi PharmaTech (Cayman) Inc. (NYSE:WX), saying the deal is too risky.
Neuberger Berman LLC, in a June 16 letter ... |
| How is AI moving the needle in the pharmaceutical industry? | Artificial intelligence (AI) is shaking up the healthcare industry. With applications in drug discovery, medical imaging, disease modeling and clinical trial conduct, it promises to revolutionize the ways in which we perform research, treat... |
| Charles River, Wuxi PharmTech still on a roller coaster | It’s been a busy week for everyone concerned with a proposed, $1.6 billion merger between Charles River Laboratories International Inc. (NYSE: CRL) and WuXi PharmaTech (Cayman) Inc. (NYSE:WX).
Aiming to counter stiff opposition from some of... |
| Bankruptcy court extends Cetero bidding deadline to May 11 | Cetero Research‘s unsecured creditors will have a little more time to prepare a bid to buy the bankrupt clinical research organization.
The bankruptcy court has extended the bid deadline for the CRO by 11 days to May 11, Outsourcing Pharma,... |
| Precision medicine will have a transformative effect on clinical trials | Evidentiary data has always had a tremendous impact on medical research. Much of that data has been generated via traditional clinical trials, which are often costly, lengthy and resource intensive but have played an important role in advan... |
| 🛍 Consolidation Begins in Live Shopping with Popshop Live Acquisition
🔦 Spotlight
🤝 Venture Deals
✨Featured Event✨
📅 LA Tech Calendar
🎧 What We’re Listening To
📙 What We’re Reading
🤝 Venture Deals
🤝 Venture Deals
📅 LA Tech Calendar
📙 What We’re Reading | 🔦 Spotlight
LA-based Popshop Live, a mobile live shopping marketplace was acquired this week by CommentSold, a Huntsville, Alabama-based live selling technology provider. Never heard of live shopping? Fear not, you are in good company. Less... |
